Parkinson disease (PD) is a neurodegenerative disorder with unknown causes. More than 1 million people in the United States have PD, and PD affects approximately 1 in 100 Americans older than 60 years.[@b1-asm-1-12] Although PD typically presents in a sporadic fashion, between 10% and 15% of PD patients have a family history of the disease, indicating that there is a strong genetic basis for this disease.[@b2-asm-1-12]

Monoamine oxidase B (MAOB) is one of the primary enzymes regulating metabolism of neurotransmitters such as dopamine. It catalyzes the production of hydrogen peroxide, and it activates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to MPP+ a toxic metabolite that can cause parkinsonism.[@b3-asm-1-12] Steventon et al. showed that patients with PD had higher platelet MAOB activity than control individuals. [@b4-asm-1-12] In addition, MAOB activity increases with age as does predisposition toward PD, which has also been linked to increased oxidative stress.[@b5-asm-1-12] Furthermore, it is well documented that MAOB inhibition may prevent degeneration of the dopaminergic system in PD.[@b6-asm-1-12] Therefore, MAOB may play a critical role in the development of PD.

The MAOB gene is located on the X chromosome. It contains a single-stranded conformational polymorphism in intron 13, a transitional conversion of adenine (A) to guanine (G) at 36 bp upstream from the 5′ end of exon 14 (A644G, rs1799836). This polymorphism is associated with varying enzyme activity. The G allele of MAOB A644G polymorphism is associated with lower brain MAOB activity, and A allele is associated with higher mRNA levels of MAOB.[@b7-asm-1-12] A number of papers investigated the relationship between this polymorphism and PD risk. However, the results remained inconclusive.[@b8-asm-1-12]--[@b27-asm-1-12] Meta-analysis is a useful method for investigating the relationship s between genetic factors and diseases, because a quantitative approach is used to combine the results from different studies on the same topic, thereby providing more reliable conclusions. Thus, we performed a meta-analysis to clarify the relationship of MAOB A644G polymorphism with PD risk. To our knowledge, this is the most comprehensive meta-analysis of the relationship between MAOB A644G polymorphism and PD risk.

METHODS
=======

Search for publications
-----------------------

In our meta-analysis, we searched the articles using the search terms "MAOB," "monoamine oxidase B," "Parkinson disease," and "polymorphism" in the PubMed, Embase, and CNKI databases, and the last search updated on March 2013. Additional studies were identified by a hand search of references of original studies or review articles on the relationship between MAOB A644G polymorphism and PD risk. No publication date or language restrictions were imposed.

Inclusion and exclusion criteria
--------------------------------

The following inclusion criteria were used: (1) the study should have evaluated the relationship between MAOB A644G polymorphism and PD risk, (2) the study should have had a case--control design, and (3) sufficient data should have been provided to calculate odds ratios (OR) and 95% confidence intervals (CI). Studies were excluded if any of the following conditions applied: (1) irrelevant to PD, MAOB, or MAOB A644G polymorphism and PD risk, (2) abstract or review, (3) genotype frequencies not reported, (4) non-clinical study, and (5) studies repeated studies or overlapped publications.

Data extraction
---------------

Two investigators independently extracted data and reached a consensus on the following characteristics of the selected studies: the first author's name, year of publication, country, ethnicity of the study population, gender, genotyping method, and numbers of cases and controls with various genotypes.

Statistical analysis
--------------------

The strength of relationship between MAOB A644G polymorphism and PD risk was accessed by calculating ORs with 95% CIs. For this meta-analysis, we examined the recessive genetic model (AA \[A\] vs AG + GG \[G\]) because allele A is a risk allele for PD, and data were commonly presented either in this format or convertible to this format. The random-effects model (the DerSimonian and Laird method) was used. A chi-square test was used to determine if genotype distribution of the female control population reported conformed to Hardy-Weinberg equilibrium (HWE) (*P*\<.05 was considered significant). Heterogeneity assumption was checked by the I2 statistic to quantify the proportion of the total variation towing to heterogeneity, and I^2^ value less than 50% indicates a lack of heterogeneity among studies. Subgroup analyses were performed by ethnicity, gender, and smoking status. Cumulative meta-analysis was done. Furthermore, sensitivity analysis was performed by sequential omission of individual studies. Galbraith plot was used to spot the outliers that were the sources of heterogeneity. Funnel plot and Egger test were used to detect publication bias.[@b28-asm-1-12] Analyses were performed using STATA 11.0 software (StataCorp LP, College Station, Texas, USA).

RESULTS
=======

Characteristics of studies
--------------------------

A total of 20 case--control studies ([Figure 1](#f1-asm-1-12){ref-type="fig"}) with 6354 subjects on the relationship between MAOB A644G polymorphism and PD risk were included for this meta-analysis.[@b8-asm-1-12]--[@b27-asm-1-12] The study involved 8 studies of Caucasian population and 12 studies of Asian population. All studies indicated that the distribution of genotypes in the female controls was consistent with HWE. The characteristics of each case--control study and the genotype in each case--control study are presented in [Tables 1](#t1-asm-1-12){ref-type="table"} and [2](#t2-asm-1-12){ref-type="table"}.

Results of meta-analyses
------------------------

As shown in [Figure 2](#f2-asm-1-12){ref-type="fig"}, the overall OR was 1.32 (95% CI 1.18--1.47), and the Z-test value for the overall effect was 4.80 (*P*\<.001) for the AA (A) vs AG + GG (G). Subgroup analysis by ethnicity was performed. For ethnicity, the populations were stratified into 2 groups: Asian (1865 cases and 2069 controls) and Caucasian (981 cases and 1439 controls). Significant relationships with PD risk in these populations were observed: Asian (OR=1.28, 95% CI 1.10--1.49, *P*=.001) and Caucasian (OR=1.37, 95% CI 1.15--1.62, *P*\<.001). Besides, subgroup analyses by gender also found significant relationships between MAOB A644G polymorphism and PD risk in females and males ([Table 2](#t2-asm-1-12){ref-type="table"}).

With regard to the cumulative meta-analysis, evidence was observed to support a significant relationship of MAOB A644G polymorphism with the susceptibility to PD ([Figure 3](#f3-asm-1-12){ref-type="fig"}). As shown in [Figure 4](#f4-asm-1-12){ref-type="fig"}, sensitivity analysis did not influence the result excessively by omitting any single study.

Funnel plot and Egger test were both performed to access the publication bias of this meta-analysis. The shape of the funnel plot seemed symmetrical, and *P* values of the Egger test was .116 ([Figure 5](#f5-asm-1-12){ref-type="fig"}), providing statistical evidence of the funnel plot symmetry.

DISCUSSION
==========

This present meta-analysis investigated the relationship between MAOB A644G polymorphism and PD risk. Twenty case--control studies with a total of 6354 subjects were eligible. At the overall analysis, MAOB A644G polymorphism seemed to be associated with PD risk. In addition, subgroup analyses by ethnicity and gender also found significant relationships. Moreover, to investigate the stability of the result, we performed sensitivity analyses. The removal of each study did not alter the result, suggesting the reliability of our result. The cumulative meta-analysis showed a trend of significant relationship between MAOB A644G polymorphism and the PD risk as data accumulated each year. Again, this procedure proved that our result was robust. Thus, results from this meta-analysis suggested that MAOB A644G polymorphism was significantly associated with PD risk.

MAOB plays an important role in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. Increased levels of MAOB mRNA and enzymatic activity have been reported in platelets from patients with PD.[@b4-asm-1-12] Additionally, Jakubauskiene et al. indicated that enhanced MAOB protein levels in platelets might be used as a disease marker of PD.[@b29-asm-1-12] Several DNA polymorphisms in the MAOB gene have been described. The only single-nucleotide polymorphism found in all human populations is the G/A dimorphism in the intron 13 sequence. The molecular analysis of MAOB polymorphism demonstrated that MAOB A644G polymorphism leads to an alterative MAOB activity.[@b7-asm-1-12] Thus, we hypothesized that MAOB A644G polymorphism could influence the susceptibility to PD. Our results supported a genetic relationship between this polymorphism and susceptibility to PD.

One of the major concerns in a sound meta-analysis is the degree of heterogeneity that exists between the component studies because non-homogeneous data are liable to result in misleading results. In the present study, the I^2^ statistics was carried out to test the significance of heterogeneity. Moderate heterogeneity between studies was observed in overall comparisons. In an attempt to find the sources of heterogeneity, subgroup analysis was performed. The heterogeneity was significantly reduced in the subgroup analysis by gender. Moreover, we re-analyzed the relationship in the female and male subgroups; the conclusions were consistent. Another important issue for any meta-analysis is publication bias owing to the selective publication of reports. In the current study, funnel plot and Egger test were performed to evaluate this problem. Both the shape of funnel plots and the statistical results did not show publication bias.

Some possible limitations in this meta-analysis should be acknowledged. First, only the published studies that were included in the selected electronic databases were identified; it is possible that some relevant published or unpublished studies may have been missed. Second, the effect of gene--gene and gene--environment interactions was not addressed in this meta-analysis because of the limited available data. Third, our meta-analysis was based on the unadjusted OR estimates because not all published studies presented adjusted ORs.

In conclusion, this meta-analysis suggests that MAOB A644G polymorphism may be associated with PD development. Further studies can assess the possible gene--environment and gene--gene interactions in the relationship between this polymorphism and PD risk.
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###### 

Characteristics of the case--control studies included in meta-analysis.

  First author         Year   Country     Ethnicity   Gender   Case   Control   Case   Control   Genotyping         
  -------------------- ------ ----------- ----------- -------- ------ --------- ------ --------- ------------ ----- ---------------------
  Kurth                1993   USA         Caucasian   M, F     64     177       25     39        36           141   PCR-SSCP
  Morimoto             1995   Japan       Asian       M, F     83     76        60     23        54           22    PCR-SSCP
  Costa                1997   USA         Caucasian   M, F     62     79        26     36        23           56    PCR-SSCP
  Hwang                1997   China       Asian       M, F     65     108       49     16        76           32    PCR-SSCP
  Checkoway            1998   USA         Caucasian   M, F     82     118       52     30        58           60    PCR-SSCP
  Mellick              1999   Australia   Caucasian   M, F     80     110       30     50        36           74    PCR-SSCP
  Shao                 2000   China       Asian       M, F     126    136       66     65        62           74    PCR-SSCP
  Wu                   2001   China       Asian       M, F     220    191       37     183       17           174   PCR-SSCP
  Hernán               2002   USA         Caucasian   M, F     214    449       86     128       196          253   Allele-specific PCR
  Kelada               2002   USA         Caucasian   M, F     186    296       106    80        138          158   PCR-SSCP
  Tan                  2003   Singapore   Asian       M, F     230    241       171    59        176          65    PCR-SSCP
  Jiang                2004   China       Asian       M, F     266    154       207    59        114          40    PCR-SSCP
  Białecka             2005   Poland      Caucasian   M, F     210    152       100    110       63           89    PCR-SSCP
  Singh                2008   India       Asian       M, F     70     100       30     37        33           37    PCR-SSCP
  Gu                   2010   China       Asian       M, F     176    354       153    23        323          31    DHPLC
  Wang                 2010   China       Asian       M, F     125    66        88     37        34           32    PCR-SSCP
  Kiyohara             2011   Japan       Asian       M, F     238    369       192    46        273          96    PCR-SSCP
  Li                   2011   China       Asian       M, F     166    170       111    55        103          67    PCR-RFLP
  Torkaman-Boutorabi   2012   Iran        Caucasian   M, F     103    70        75     28        44           26    PCR-RFLP
  Zeng                 2012   China       Asian       M, F     95     104       67     28        71           33    PCR-RFLP

M: male, F: female, MF: male and female, PCR: polymerase chain reaction, SSCP: single-stranded conformational polymorphism, RFLP: restriction fragment length polymorphism, DHPLC: denaturing high-performance liquid chromatography.

###### 

Summary of different results of the association between MAOB A644G polymorphism and the risk of Parkinson disease.

  Comparison                        Sample size   No.    Test of association   Heterogeneity                                        
  --------------------- ----------- ------------- ------ --------------------- ------------------ ------ -------- --- ------- ----- ------
  AA (A) vs AG+GG (G)   Overall     2846          3508   20                    1.32(1.18--1.47)   4.80   \<.001   F   24.45   .18   22.0
  AA (A) vs AG+GG (G)   Asian       1865          2069   12                    1.28(1.10--1.49)   3.22   .001     F   13.25   .28   17.0
  AA (A) vs AG+GG (G)   Caucasian   981           1439   8                     1.37(1.15--1.62)   3.62   \<.001   F   10.80   .15   35.0
  A vs G                Male        1038          1143   12                    1.49(1.22--1.81)   3.97   \<.001   F   4.29    .96   0
  AA vs AG+GG           Female      764           970    12                    1.32(1.06--1.64)   2.45   .01      F   6.99    .80   0

F: Fixed-effects model.
